NCT07464925 2026-03-20
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
Tetragon Biosciences Ltd
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Coherence Neuro Australia Pty Limited
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Leica Microsystems (Schweiz) AG
Neonc Technologies, Inc.
ImmVira Pharma Co. Ltd
Leica Microsystems (Schweiz) AG
Philogen S.p.A.
Servier (Tianjin) Pharmaceutical Co. LTD.
Suzhou Maximum Bio-tech Co., Ltd.
Power Life Sciences Inc.
Epitopoietic Research Corporation